PubMed Health⌕ Search

Biomedical subjects

J K Iglehart

Publications and source records attributed to J K Iglehart.

17 recordsLinked to original sources
PubMed1979

Update on HMOs.

Explore the source record for details and available documents.

Health Maintenance Organizations↗
PubMed1978

The Carter administration's health budget: charting new priorities with limited dollars.

Although the budget is described by the Administration as a "full statement of its priorities," policy and spending are bound by past decisions. New program initiatives are limited to a few discretionary programs under the Public Health Service, but the massive budget does reveal personal preferences of the President and the Secretary. Some of these choices may not find congressional favor; yet the entire budget process shows the Democrats again endorsing the categorical approach reminiscent of the New Deal and the Great Society.

Budgets↗
PubMed1978

Priorities for a national health policy: cost control and disease prevention.

Despite some progress on the national health care scene, the cost spiral looms as the major problem to be tacked now, forcing moves toward a revamped national health plan into the wings. Health care organizations with access to the administration, however, should design detailed disease prevention plans--which will not require immediate huge expenditures--and should develop the date to show their cost effectiveness.

Cost-Benefit Analysis↗
PubMed1977

Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin.

A number of continuous, human lymphoid cell lines from healthy and leukemic donors have been studied. Those from healthy individuals were found to be cystine prototrophs (cys+), while those from leukemic donors were observed to be cystine auxotrophs (cys-). The former can grow in either cystine or cystathionine-containing media. The latter grow only in cystine-containing medium. The former contain readily measurable levels of cystathionase, the last enzyme in the mammalian cysteine biosynthetic pathway, while the latter contain much less of this activity. The apparent molecular weight, overall charge, pH versus activity, Km, and [pyridoxal phosphate] versus activity properties of the enzyme from both cell types were indistinguishable. No soluble cystathionase inhibitor could be detected in cys- cell lines. Thus, it is reasonable to hypothesize that those leukemic cell lines studied synthesize less active cystathionase protein than their cys+ counterparts and that this difference in enzyme production underlies the differential growth properties in cystathionine-containing medium.

Animals↗